Related Experiment Videos
Serum lactate dehydrogenase isoenzyme-1 in children with yolk sac tumor
Insights
Elevated serum lactate dehydrogenase isoenzyme-1 (LDH-1) is linked to childhood yolk sac tumors (YST), a type of germ cell tumor (GCT). This marker aids in monitoring YST during treatment.
Area of Science:
- Pediatric Oncology
- Biochemistry
- Tumor Markers
Background:
- Germ cell tumors (GCTs) are common in childhood.
- Yolk sac tumors (YSTs) are a frequent subtype of pediatric GCT.
- Elevated serum lactate dehydrogenase isoenzyme-1 (LDH-1) has been observed in GCT patients.
Purpose of the Study:
- To investigate the significance of serum LDH-1 in pediatric yolk sac tumors (YST).
- To evaluate LDH-1 as a potential tumor marker for YST monitoring.
Main Methods:
- Serum LDH isoenzymes were analyzed in eight children diagnosed with YST.
- Serial serum LDH-1 levels were monitored during treatment.
- LDH isoenzyme patterns in tumor tissues were examined.
Main Results:
- Seven out of eight pediatric YST patients showed elevated serum LDH-1 levels.
- One patient in an early stage did not exhibit elevated LDH-1.
- Increased LDH-1 levels are presumed to originate from tumor tissues.
Conclusions:
- Serum LDH-1 is a potentially valuable tumor marker for pediatric yolk sac tumors (YST).
- LDH-1 elevation is associated with the broader spectrum of germ cell tumors (GCT).
- LDH-1 can be utilized for monitoring YST during therapeutic interventions.
Abstract:
Although in recent years the evidence of an increase in serum lactate dehydrogenase isoenzyme-1 (LDH-1) in patients with germ cell tumor (GCT) has attracted attention, there have only been a few reports concerning yolk sac tumor (YST), which is a frequent type of GCT in childhood. Serum LDH isoenzymes were determined in eight children with YST, and an increase in LDH-1 was found in seven of them, excluding one in an early stage. On the basis of the findings of serial serum LDH-1 levels during treatment and of LDH isoenzyme pattern in tumor tissues, it is presumed that the increased serum LDH-1 is derived from tumor tissues. LDH-1 seems to be useful as a tumor marker, not specific for YST but associated with the whole spectrum of GCT, for monitoring of YST.